Keytruda for neoadjuvant therapy of triple negative breat cancer – pro
Pembrolizumab was also tested as a neoadjuvant therapy for locally advanced TNBC in the phase Ib KEYNOTE-173 study. There is also evidence supporting its use for Triple Negative Breast Cancer. The pembrolizumab along with chemotherapy offered better progression-free survival than chemotherapy alone as the first treatment for metastatic triple-negative breast cancer or recurrent triple-negative breast cancer. Keytruda and specificity for triple-negative cancer.
Keung EZ, Ukponmwan EU, Cogdill AP, Wargo JA. The Rationale and Emerging Use of Neoadjuvant Immune Checkpoint Blockade for Solid Malignancies. Ann Surg Oncol. 2018;25(7):1814-1827. doi:10.1245/s10434-018-6379-8
M. Myashita et al, Review Article on Neoadjuvant/adjuvant Treatment for Early Breast Cancer CCO Vol 9, No 3 (June 2020)
Schmid P, Park YH, Muñoz-Couselo E, et al. Pembrolizumab 1 chemotherapy as neoadjuvant treatment for triple negative breast cancer (TNBC): preliminary results from KEYNOTE-173. J Clin Oncol 2017;35:556